|Bid||319.00 x 1000|
|Ask||326.50 x 900|
|Day's Range||318.34 - 328.31|
|52 Week Range||263.30 - 380.76|
|Beta (5Y Monthly)||1.04|
|PE Ratio (TTM)||48.90|
|Earnings Date||Jan 28, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||345.56|
Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Illumina (NASDAQ:ILMN) news for Monday includes ILMN stock falling on a weak outlook for 2020.Source: Shutterstock The negative Illumina news comes directly from CEO Francis deSouza. During a presentation at the JPMorgan Healthcare Conference, he said that 2020 revenue growth is expected to come in between 9% and 11%.The bad Illumina news here is that Wall Street is expecting stronger revenue growth for the full year of 2020. To be more clear, analysts are looking for ILMN's revenue growth to reach 12% in 2020, reports SeekingAlpha.InvestorPlace - Stock Market News, Stock Advice & Trading TipsIllumina's poor outlook for 2020 isn't the only recent news for the company. It also announced today that it has signed a 15-year deal with Roche Partner. This deal is non-exclusive and will focus on increasing the adoption of distributable next-generation sequencing-based testing in oncology.The deal will have Roche Partner developing, manufacturing and commercializing "AVENIO IVD tests for both tissue and blood for use on Illumina's NextSeq 550Dx System." * 7 Inflation-Beating REITs to Ground Your Income Portfolio Omead Ostadan, Senior Vice President of Marketing and Products at Illumina, says this about the ILMN stock news."We are proud to continue our tradition of driving down the cost of sequencing without compromising accuracy. NextSeq 1000 and 2000 are designed to enable core labs, small to medium research labs and clinical facilities to access high intensity sequencing applications using our industry-leading SBS technology."ILMN stock was down 4.04% as of Monday afternoon.As of this writing, William White did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Inflation-Beating REITs to Ground Your Income Portfolio * 7 Healthcare Stocks to Buy or Sell As Pricing Pressures Mount * 7 Earnings Reports to Watch This Week The post Illumina News: ILMN Stock 4% Lower on Weak 2020 Outlook appeared first on InvestorPlace.
Illumina, Inc. (NASDAQ: ILMN) further demonstrated its commitment to making genomics more accessible for the potential benefit of patients today with a series of technology and partnership announcements that further the company’s commitment to unlocking the power of the genome.
Illumina, Inc. (NASDAQ: ILMN), the global leader in DNA sequencing and array-based technologies, and Roche, a global pioneer in pharmaceuticals and diagnostics, today announced a 15-year, non-exclusive collaboration agreement to broaden the adoption of distributable next-generation sequencing-based (NGS) testing in oncology. As the understanding of genomic drivers of cancer evolves, NGS has the potential to transform cancer risk prediction, detection, diagnosis, treatment and monitoring.
ArcherDX, Inc. today announced a non-exclusive, multi-year partnership with Illumina, Inc. (NASDAQ: ILMN) intended to broaden access of next generation sequencing (NGS)-based oncology testing, including companion diagnostics for therapeutic selection, personalized monitoring, and recurrence surveillance IVD tests, upon FDA approval, enabling more patient access to world-class care in their own community, delivered by local clinicians.
Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Biotech firm Illumina, Inc. (ILMN) scrapped a merger with Pacific Biosciences, but there's still a lot to like about Illumina and for investors that can't handle the stock's over $300 price tag, the ARK Genomic Revolution Multi-Sector Fund (ARKG) is an adequate proxy on the stock. ARKG allocates 10.38% of its weight to shares of Illumina, making it the ETF with the largest weight to that stock. ARKG's stablemate, the ARK Innovation ETF (ARKK) , is second with an Illumina weight of about 7%.
Genetic sequencing giant Illumina Inc. has nixed its $1.2 billion acquisition attempt of Menlo Park's Pacific Biosciences amid intense regulator scrutiny. San Diego-based Illumina announced the all-cash deal to purchase its smaller competitor in 2018, but it has faced an uphill battle to convince regulators in the U.S. and Europe. In October, antitrust regulators in the UK put out a statement of concern about the proposed merger given Illumina's immense market power in the highly-concentrated DNA sequencing industry.
Per Illumina (ILMN), the lengthy route to achieve regulatory nods for the transaction induces uncertainty about the ultimate outcome of the integration.
The two companies, which both sell DNA sequencing tools, announced on Thursday that they had decided to cancel their proposed merger.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Jan. 2) Agile Therapeutics Inc (NASDAQ: AGRX (announced the ...
U.S. stock futures sink and oil prices surge after a U.S. military strike kills Gen. Qassem Soleimani, a top Iranian general; the U.S. economic calendar includes the ISM Manufacturing Index for December and minutes from the Federal Reserve's Dec. 10-11 meeting; Illumina abandons $1.2 billion acquisition of Pacific Biosciences.
(Bloomberg) -- Illumina Inc. and Pacific Biosciences of California Inc. called off their planned $1.2 billion deal after U.S. antitrust enforcers last month moved to block the merger of the DNA-sequencing companies.The transaction had been on hold for more than a year after being announced in November 2018. But antitrust authorities in the U.S. and the U.K. had pushed back against it, and the U.S. Federal Trade Commission filed a complaint to block it last month.“Considering the lengthy regulatory approval process the transaction has already been subject to and continued uncertainty of the ultimate outcome, the parties decided that terminating the agreement” was the best option, the companies said in a joint statement Thursday.Both companies make DNA sequencing machines, a fast-growing segment of the biotechnology and medical sectors driven by demand from drugmakers, hospitals and research institutions. Illumina will pay Pacific Biosciences a $98 million termination fee.Shares of Menlo Park, California-based Pacific Biosciences gained 3.5% to $5.34 per share in New York trading after the markets closed; the stock had been trading well below the deal’s $8-a-share value. Illumina shares were unchanged.Gail Levine, deputy director of the FTC’s Bureau of Competition, said in a statement Thursday that calling off the deal would preserve a more vibrant market.“This deal threatened to let a monopolist extinguish nascent competition in a growing health care market: next-generation DNA sequencing. Customers across the United States and the world will now continue to benefit from the independent innovative efforts of these companies to develop faster, better, and less expensive next-generation DNA sequencing technologies,” Levine said.Her remarks echoed comments in December when the commission moved to block the transaction. And Illumina said at the time it would keep working to get the deal through while examining its options. “It is not clear that we will be able to secure the required regulatory approvals to allow this transaction to close,” Illumina spokesman Eric Endicott said in an email Thursday. “We believe it is in the best interest of both companies’ shareholders and employees to terminate this agreement now.”One recent analysis by Morningstar Inc. estimated that Illumina controls more that 70% of the market for sequencing the human genome. Its DNA-sequencing machines range from bench-top devices to high-end sequencers that can cost as much as $1 million each, and are used in drug discovery, medicine, biological research and consumer testing.Pacific Biosciences’s machines use a different type of technology, which can decode extensive stretches of DNA with a high degree of accuracy. Unlike the technology Illumina’s machines use, it can read some particularly difficult-to-analyze circumstances. At the time the deal was announced, Illumina said the takeover could help lower the cost of long-read sequencing from $12,000 to $1,000.(Updates Pacific Biosciences shares in the fifth paragraph)\--With assistance from David McLaughlin.To contact the reporter on this story: Kristen V. Brown in San Francisco at firstname.lastname@example.orgTo contact the editors responsible for this story: Drew Armstrong at email@example.com, Timothy AnnettFor more articles like this, please visit us at bloomberg.com©2020 Bloomberg L.P.
Illumina Inc. and Pacific Biosciences of California Inc. on Thursday said they have agreed to drop plans to merge. Under the merger agreement, announced Nov. 1, Illumina would have paid $1.2 billion in cash for Pacific Biosciences. The news sent Pacific Biosciences shares down 3% in after-hours trading. The lengthy regulatory approval process required for the transaction "has already been subject to and continued uncertainty of the ultimate outcome," the companies said in a joint news release. As part of the merger agreement, Illumina will pay Pacific Biosciences a termination fee of $98 million. The announcement was made after markets closed.
Illumina, Inc. (NASDAQ:ILMN) and Pacific Biosciences of California, Inc. (NASDAQ:PACB) today announced that they have mutually agreed to terminate their merger agreement, previously announced on November 1, 2018, under which Illumina would acquire Pacific Biosciences at a fully diluted enterprise value of approximately $1.2 billion in an all-cash transaction.
Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, stiff competition remains a woe.
It has been a fantastic year for equity investors as Donald Trump pressured Federal Reserve to reduce interest rates and finalized the first leg of a trade deal with China. If you were a passive index fund investor, you had seen gains of 31% in your equity portfolio in 2019. However, if you were an […]